FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036094758> ?p ?o ?g. }

• W3036094758 endingPage "2657" @default.
• W3036094758 startingPage "2647" @default.
• W3036094758 abstract "PURPOSE We report a multicenter controlled trial comparing renal recovery and tolerance profile of doublet versus triplet bortezomib-based regimens in patients with initial myeloma cast nephropathy (CN) and acute kidney injury (AKI) without need for dialysis. METHODS After symptomatic measures and high-dose dexamethasone, patients were randomly assigned to receive bortezomib plus dexamethasone (BD), or BD plus cyclophosphamide (C-BD). In patients with < 50% reduction of serum free light chains (sFLCs) after 3 cycles, chemotherapy was reinforced with either cyclophosphamide (BD group) or thalidomide (C-BD group). RESULTS Ninety-two patients were enrolled in each group. At random assignment, characteristics of the 2 groups were similar, including median age (68 years) and serum creatinine level (305.5 and 273.5 µmol/L in BD and C-BD group, respectively). At 3 months, renal response rate (primary end point) was not different (41 v 47 responders in the BD and C-BD groups, respectively; relative risk [RR], 0.87; P = .46). Very good partial response (free light chain reduction ≥ 90%) or more was achieved in 36 and 47 patients, respectively (RR, 0.76; P = .10). After 1 cycle of chemotherapy, 69 in the BD group and 67 patients in the C-BD group had achieved sFLC level ≤ 500 mg/L. Serious adverse events were recorded in 30 and 40 patients, respectively. At 12 months, 19 patients had died (9 in the BD group v 10 in the C-BD group), including 10 (6 in the BD group and 4 in the C-BD group) from myeloma progression and 3 (0 in the BD group and 3 in the C-BD group) from infection. Within median follow-up of 27 months, 43 and 42 patients switched to new therapy, respectively. Overall, 50 patients (24 in the BD group and 26 in the C-BD group) had died. CONCLUSION This randomized study did not show any benefit of C-BD compared with BD on renal recovery of patients with initial CN not requiring dialysis. Adding cyclophosphamide did not sufficiently improve the efficacy-toxicity balance. Patients with myeloma with AKI are fragile, and indication for doublet or triplet regimen should be adapted to frailty." @default.
• W3036094758 created "2020-06-25" @default.
• W3036094758 creator A5000761302 @default.
• W3036094758 creator A5001789644 @default.
• W3036094758 creator A5013599527 @default.
• W3036094758 creator A5016941619 @default.
• W3036094758 creator A5025424518 @default.
• W3036094758 creator A5027311948 @default.
• W3036094758 creator A5033775906 @default.
• W3036094758 creator A5036677725 @default.
• W3036094758 creator A5042283595 @default.
• W3036094758 creator A5043970581 @default.
• W3036094758 creator A5047018311 @default.
• W3036094758 creator A5051532946 @default.
• W3036094758 creator A5052673276 @default.
• W3036094758 creator A5059590275 @default.
• W3036094758 creator A5062922816 @default.
• W3036094758 creator A5069447323 @default.
• W3036094758 creator A5069745915 @default.
• W3036094758 creator A5075950291 @default.
• W3036094758 creator A5076266774 @default.
• W3036094758 creator A5077081397 @default.
• W3036094758 creator A5077603727 @default.
• W3036094758 creator A5082515837 @default.
• W3036094758 creator A5083826444 @default.
• W3036094758 creator A5085216100 @default.
• W3036094758 creator A5086896620 @default.
• W3036094758 creator A5089880659 @default.
• W3036094758 creator A5091002248 @default.
• W3036094758 date "2020-08-10" @default.
• W3036094758 modified "2023-10-18" @default.
• W3036094758 title "Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy" @default.
• W3036094758 cites W1966809384 @default.
• W3036094758 cites W1967300023 @default.
• W3036094758 cites W1990148510 @default.
• W3036094758 cites W1994249743 @default.
• W3036094758 cites W2003664440 @default.
• W3036094758 cites W2018049995 @default.
• W3036094758 cites W2050829096 @default.
• W3036094758 cites W2054072744 @default.
• W3036094758 cites W2054708881 @default.
• W3036094758 cites W2073742622 @default.
• W3036094758 cites W2095328443 @default.
• W3036094758 cites W2095494110 @default.
• W3036094758 cites W2099320310 @default.
• W3036094758 cites W2110608811 @default.
• W3036094758 cites W2124211478 @default.
• W3036094758 cites W2125679118 @default.
• W3036094758 cites W2141723966 @default.
• W3036094758 cites W2146429012 @default.
• W3036094758 cites W2151595053 @default.
• W3036094758 cites W2164807675 @default.
• W3036094758 cites W2193716145 @default.
• W3036094758 cites W2277498048 @default.
• W3036094758 cites W2284914514 @default.
• W3036094758 cites W2299833483 @default.
• W3036094758 cites W2319764074 @default.
• W3036094758 cites W2416137380 @default.
• W3036094758 cites W2512106959 @default.
• W3036094758 cites W2528329272 @default.
• W3036094758 cites W2567188480 @default.
• W3036094758 cites W2593723184 @default.
• W3036094758 cites W2774525828 @default.
• W3036094758 cites W2785647909 @default.
• W3036094758 cites W2902348661 @default.
• W3036094758 cites W2920943859 @default.
• W3036094758 cites W2942710216 @default.
• W3036094758 cites W2945852816 @default.
• W3036094758 cites W2948728876 @default.
• W3036094758 cites W2954456641 @default.
• W3036094758 cites W2988984460 @default.
• W3036094758 cites W3012328912 @default.
• W3036094758 doi "https://doi.org/10.1200/jco.20.00298" @default.
• W3036094758 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32574117" @default.
• W3036094758 hasPublicationYear "2020" @default.
• W3036094758 type Work @default.
• W3036094758 sameAs 3036094758 @default.
• W3036094758 citedByCount "21" @default.
• W3036094758 countsByYear W30360947582020 @default.
• W3036094758 countsByYear W30360947582021 @default.
• W3036094758 countsByYear W30360947582022 @default.
• W3036094758 countsByYear W30360947582023 @default.
• W3036094758 crossrefType "journal-article" @default.
• W3036094758 hasAuthorship W3036094758A5000761302 @default.
• W3036094758 hasAuthorship W3036094758A5001789644 @default.
• W3036094758 hasAuthorship W3036094758A5013599527 @default.
• W3036094758 hasAuthorship W3036094758A5016941619 @default.
• W3036094758 hasAuthorship W3036094758A5025424518 @default.
• W3036094758 hasAuthorship W3036094758A5027311948 @default.
• W3036094758 hasAuthorship W3036094758A5033775906 @default.
• W3036094758 hasAuthorship W3036094758A5036677725 @default.
• W3036094758 hasAuthorship W3036094758A5042283595 @default.
• W3036094758 hasAuthorship W3036094758A5043970581 @default.
• W3036094758 hasAuthorship W3036094758A5047018311 @default.
• W3036094758 hasAuthorship W3036094758A5051532946 @default.
• W3036094758 hasAuthorship W3036094758A5052673276 @default.
• W3036094758 hasAuthorship W3036094758A5059590275 @default.
• W3036094758 hasAuthorship W3036094758A5062922816 @default.

• next